Galderma Targets Amneal’s Generic Rosacea Treatment
The lawsuit claims that Amneal's recent filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to produce a generic version of 40 mg doxycycline delayed-release capsules infringes three patents, one held by Supernus and two held by Galderma.
The plaintiffs are seeking a ruling that...
Already a subscriber? Click here to login